• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002644.SZ
Share

LanZhou Foci Pharmaceutical Co.,Ltd. Stocks

CN¥ 8.19Last Updated 09.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 629.16M

CN¥ 8.19
Key Takeaways

Risk factor

Sufficiently resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

LanZhou Foci Pharmaceutical Co.,Ltd. is a prominent pharmaceutical entity based in China, primarily focused on the manufacturing and distribution of traditional Chinese medicines. Its diverse product line, offered under the "Min Shan" and "Foci" brand names, encompasses a variety of formats, including pills, tablets, capsules, and granules. Beyond its production activities, the company actively pursues research and development initiatives aimed at pioneering novel herbal remedies. Its global footprint extends to approximately 27 countries, with key export markets including the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, and Hong Kong. Established in 1929, the firm's headquarters are located in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of the Lanzhou Foci Pharmaceutical Factory.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 00:49

Trump announced an "energy truce" between Ukraine and Russia. What do analysts think?

11.10.2026 21:01

A Warning Sign for the AI Market: DeepSeek Seeks $12 Billion—Key Details on the IPO as of October 11

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026